Skip to main content
. 2022 Feb 1;13:746678. doi: 10.3389/fpsyt.2022.746678

Table 1.

Study characteristics of the network analyzed samples.

Study name Year N (Post-treatment) Mean age Gender (N Male) Intervention Symptom measure(s)
Altenstein-Yamanaka 2017 63 39.65 29 CBT BDI-II
Azvedo da Silva 2017 30 24.07 8 CBT HRSD-17
Basu 2017 87 35.12 73 Escitalopram MADRS
Bernecker 2016 32 45.58 10 CBT HRSD-17
Carter 2013 37 39.11 13 CBT BDI-II (N = 35), HRSD-17 (N = 36), MADRS (N = 37)
Ciusani 2004 10 38.6 3 Venlafaxine MADRS
Forman 2007 74 29.96 10 CBT BDI-II
Groves 2015 19 34.95 9 CBT MADRS
Halaris 2015 19 38.74 5 Escitalopram HRSD-17
Heller 2013 12 29.67 7 Venlafaxine HRSD-17
Huang 2016 48 N/A N/A Escitalopram (N = 30), Mirtazapine (N = 8), Venlafaxine (N = 10) BDI-II
Lenze (IRL-GREY) 2015 392 69.01 141 Venlafaxine MADRS
Lopes 2014 16 35.56 5 CBT BDI-II
Luty 2007 71 36 22 CBT BDI-II, HRSD-17, MADRS
Myung 2012 36 66 7 Mirtazapine (N = 29), Venlafaxine (N = 7) HRSD-17
Nakagawa 2017 39 39.53 25 CBT BDI-II, HRSD-17
Saghafi 2007 171 73.02 53 Escitalopram HRSD-17
Sefarty 2009 64 74.22 11 CBT BDI-II
Sirot 2012 31 49 13 Mirtazapine HRSD-17
Soczysnka 2014 17 42 9 Escitalopram HRSD-17
Eddington 2015 22 N/A N/A CBT BDI-II
Osvath 2007 99 42.26 42 Mirtazapine HRSD-17

N/A, not available.